Search research articles
Contact Us
Filters
Showing results (21-30 of 175) with videos related to
Page
of 18
Sort By:
Therapeutic Advances in Hematology
|
October 21, 2017
Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma
Liana Nikolaenko, Robert Chen, Alex F Herrera
Experimental Hematology & Oncology
|
December 27, 2022
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
Walter Hanel, Alex F Herrera, Narendranath Epperla
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 10, 2024
Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease
Cathy Burton, Pamela Allen, Alex F Herrera
The New England Journal of Medicine
|
January 3, 2025
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply
Alex F Herrera, Michael LeBlanc, Jonathan W Friedberg
JACC. Cardiooncology
|
July 3, 2023
How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations
Swetha Kambhampati Thiruvengadam, Alex F Herrera, June-Wha Rhee
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy
Alison J Moskowitz, Alex F Herrera, Anne W Beaven
Cancer Drug Resistance (Alhambra, Calif.)
|
May 18, 2022
Barriers to achieving a cure in lymphoma
Swetha Kambhampati, Joo Y Song, Alex F Herrera, et al.
British Journal of Haematology
|
May 15, 2023
Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
Swetha Kambhampati, Evgenii Shumilov, Monica Saumoy, et al.
British Journal of Haematology
|
February 16, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas
Christina Poh, Jasmine Zain, James Godfrey, et al.
Haematologica
|
February 3, 2022
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit
Matthew Mei, Mehdi Hamadani, Kwang W Ahn, et al.
Page
of 18
Search research articles
Search
Showing results (21-30 of 175) with videos related to
Sort By:
Page
of 18
Therapeutic Advances in Hematology
|
October 21, 2017
Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma
Liana Nikolaenko, Robert Chen, Alex F Herrera
Experimental Hematology & Oncology
|
December 27, 2022
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
Walter Hanel, Alex F Herrera, Narendranath Epperla
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 10, 2024
Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease
Cathy Burton, Pamela Allen, Alex F Herrera
The New England Journal of Medicine
|
January 3, 2025
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply
Alex F Herrera, Michael LeBlanc, Jonathan W Friedberg
JACC. Cardiooncology
|
July 3, 2023
How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations
Swetha Kambhampati Thiruvengadam, Alex F Herrera, June-Wha Rhee
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy
Alison J Moskowitz, Alex F Herrera, Anne W Beaven
Cancer Drug Resistance (Alhambra, Calif.)
|
May 18, 2022
Barriers to achieving a cure in lymphoma
Swetha Kambhampati, Joo Y Song, Alex F Herrera, et al.
British Journal of Haematology
|
May 15, 2023
Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
Swetha Kambhampati, Evgenii Shumilov, Monica Saumoy, et al.
British Journal of Haematology
|
February 16, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas
Christina Poh, Jasmine Zain, James Godfrey, et al.
Haematologica
|
February 3, 2022
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit
Matthew Mei, Mehdi Hamadani, Kwang W Ahn, et al.
Page
of 18